Abstract:Nanosafety assessment has experienced an intense era of research during the past decades driven by a vivid interest of regulators, industry, and society. Toxicological assays based on in vitro cellular models have undergone an evolution from experimentation using nanoparticulate systems on singular epithelial cell models to employing advanced complex models more realistically mimicking the respective body barriers for analyzing their capacity to alter the immune state of exposed individuals. During this phase, a number of lessons were learned. We have thus arrived at a state where the next chapters have to be opened, pursuing the following objectives: (1) to elucidate underlying mechanisms, (2) to address effects on vulnerable groups, (3) to test material mixtures, and (4) to use realistic doses on (5) sophisticated models. Moreover, data reproducibility has become a significant demand. In this context, we studied the emerging concept of adverse outcome pathways (AOPs) from the perspective of immune activation and modulation resulting in pro-inflammatory versus tolerogenic responses. When considering the interaction of nanomaterials with biological systems, protein corona formation represents the relevant molecular initiating event (e.g., by potential alterations of nanomaterial-adsorbed proteins). Using this as an example, we illustrate how integrated experimental-computational workflows combining in vitro assays with in silico models aid in data enrichment and upon comprehensive ontology-annotated (meta)data upload to online repositories assure FAIRness (Findability, Accessibility, Interoperability, Reusability). Such digital twinning may, in future, assist in early-stage decision-making during therapeutic development, and hence, promote safe-by-design innovation in nanomedicine. Moreover, it may, in combination with in silico-based exposure-relevant dose-finding, serve for risk monitoring in particularly loaded areas, for example, workplaces, taking into account pre-existing health conditions. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.

Precision design of engineered nanomaterials to guide immune systems for disease treatment

Tailoring the Physicochemical Properties of Nanomaterials for Immunomodulation.

Do Engineered Nanomaterials Affect Immune Responses by Interacting With Gut Microbiota?

Impact of Inorganic/Organic Nanomaterials on the Immune System for Disease Treatment

Progress in Nanoparticle-Based Regulation of Immune Cells.

Physical and Chemical Cues at the Nano–Bio Interface for Immunomodulation

Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions

Engineered Cell Membrane‐Derived Nanoparticles in Immune Modulation

The Role of Nanomaterials in the Treatment of Diseases and Their Effects on the Immune System

Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations

Msns and Mwcnts Topical Application on Immune Toxicity and Physicochemical Properties

Insights into the epigenetic effects of nanomaterials on cells

Biocompatibility of nanomaterials and their immunological properties

Mechanisms Involved in the Impact of Engineered Nanomaterials on the Joint Toxicity with Environmental Pollutants.

Engineered Nanomaterials for Tumor Immune Microenvironment Modulation in Cancer Immunotherapy

Interactions of Nanomaterials and Biological Systems: Implications to Personalized Nanomedicine

Nanomaterials trigger functional responses in primary human immune cells

Low-dimensional nanomaterials enabled autoimmune disease treatments: Recent advances, strategies, and future challenges

Therapeutic synthetic and natural materials for immunoengineering

A comprehensive framework for evaluating the environmental health and safety implications of engineered nanomaterials

Breaking Immunosuppressive Barriers by Engineered Nanoplatforms for Turning Cold Tumor to Hot